The glyburide report card.
Over the past decade, several studies have been published describing the use of glyburide for the treatment of women with gestational diabetes (GDM). These studies include randomized prospective trials, prospective studies, and cohort studies. With a total of more than 1000 patients, they encompass a wide range of patient populations and treatment centers and demonstrate the effectiveness of oral treatment in achieving good glycemic control in women with GDM. Taken together, these studies have demonstrated that glyburide is as safe and as useful as insulin for the treament of women with GDM and will likely become universally accepted as the first line drug of choice for treatment of this condition.
Rosenn
Barak M
BM
Department of Obstetrics & Gynecology, St. Luke's Roosevelt Hospital Center, 1000 10th Ave., Suite 10-C, New York, NY10019, USA. brosenn@chpnet.org
D001786:Blood Glucose / Q000378:metabolism; D015331:Cohort Studies; D016640:Diabetes, Gestational / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D005905:Glyburide / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D005905:Glyburide